Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: Advocacy

Displaying 49 papers

Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery

Publication: Coxon GD, Cooper CB, Gillespie SH, McHugh TD. Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery. J Infect Dis. 2012 May 15;205 Suppl 2:S258-64. doi: 10.1093/infdis/jis191.

3/2012

Tags: Advocacy, Drug Discovery, Drug Targets, Editorials

New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future

Publication: Lienhardt C, Raviglione M, Spigelman M, et. al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012 May 15;205 Suppl 2:S241-9. doi: 10.1093/infdis/jis034.

3/2012

Tags: Advocacy, Childhood TB, Clinical Development, Drug Discovery, Drug-Sensitivity Testing, Editorials, Global Pipeline, MDR-TB, Moxifloxacin, Pharmacodynamics, Pharmacokinetics, Policy, Preclinical Models, Pretomanid/PA-824, Regimen Change, TB Market, TB-HIV, Trial Design

Moxifloxacin for tuberculosis

Publication: Mendel C, Springsklee M. Moxifloxacin for tuberculosis. Lancet Infect Dis. 2012 Mar;12(3):176-7; author reply 177-8. doi: 10.1016/S1473-3099(11)70351-6.

3/2012

Tags: Advocacy, Clinical Development, Drug-Sensitivity Testing, Editorials, MDR-TB, Moxifloxacin, Policy, Regimen Change

Drugs for neglected diseases: part II

Publication: Kaneko T. Drugs for neglected diseases: part II. Future Med Chem. 2011 Sep;3(11):1329-30. doi: 10.4155/fmc.11.104.

9/2011

Tags: Advocacy, Clinical Development, Drug Discovery, Editorials, Global Pipeline, TB Burden

Drug repositioning in the treatment of malaria and TB

Publication: Nzila A, Ma Z, Chibale K. Drug repositioning in the treatment of malaria and TB. Future Med Chem. 2011 Sep;3(11):1413-26. doi: 10.4155/fmc.11.95.

Author(s): Alexis Nzil, Zhenkun Ma, Kelly Chibale

9/2011

Tags: Advocacy, Editorials, MDR-TB, TB Burden, XDR-TB

Challenges and opportunities in developing novel drugs for TB

Publication: Kaneko T, Cooper C, Mdluli K. Challenges and opportunities in developing novel drugs for TB. Future Med Chem. 2011 Sep;3(11):1373-400. doi: 10.4155/fmc.11.115.

Author(s): Takushi Kaneko, Christopher Cooper, Khisimuzi Mdluli

9/2011

Tags: Advocacy, Drug Discovery, Editorials, Global Pipeline, Preclinical Models

The TB Alliance: overcoming challenges to chart the future course of TB drug development

Publication: Ginsberg AM. The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future Med Chem. 2011 Aug;3(10):1247-52. doi: 10.4155/fmc.11.82.

8/2011

Tags: Advocacy, Editorials, Global Pipeline

Drugs for neglected diseases: part I

Publication: Kaneko T. Drugs for neglected diseases: part I. Future Med Chem. 2011 Aug;3(10):1235-7. doi: 10.4155/fmc.11.103.

8/2011

Tags: Advocacy, Clinical Development, Drug Discovery, Editorials, Global Pipeline, TB Burden, TB-HIV

Towards new business models for R&D for novel antibiotics

Publication: So AD, Gupta N, Brahmachari SK, Towards new business models for R&D for novel antibiotics. Drug Resist Updat. 2011 Apr;14(2):88-94. doi: 10.1016/j.drup.2011.01.006.

3/2011

Tags: Advocacy, Editorials

Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making

Publication: Wells WA, Brooks A. Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making. Health Res Policy Syst. 2011 Mar 31;9:15. doi: 10.1186/1478-4505-9-15.

3/2011

Tags: Advocacy, Policy, Regimen Change, TB Market

Drugs in development for tuberculosis

Publication: Ginsberg AM, Drugs in development for tuberculosis. Drugs. 2010 Dec 3;70(17):2201-14. doi: 10.2165/11538170-000000000-00000.

12/2010

Tags: Advocacy, Bedaquiline (TMC-207), Clinical Development, Editorials, Global Pipeline, Pretomanid/PA-824, Rifapentine, TB Burden

Tuberculosis regimen change in high-burden countries

Publication: Wells WA, Konduri N, Chen C, et.al. Tuberculosis regimen change in high-burden countries. Int J Tuberc Lung Dis. 2010 Dec;14(12):1538-47.

12/2010

Tags: Advocacy, Editorials, Policy, Regimen Change, TB Market

Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection

Publication: Zumla A, Atun R, Maeurer M, et; al. Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health. 2010 Nov 2; doi: 10.1111/j.1365-3156.2010.02665.x

11/2010

Tags: Advocacy, Editorials, TB Burden

New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades

Publication: Spigelman M, Woosley R, Gheuens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis. 2010 Jun;14(6):663-4. http://www.ingentaconnect.com/content/iuatld/ijtld/2010/0000001

6/2010

Tags: Advocacy, Clinical Development, Editorials, MDR-TB, TB Drug Market, TB Market, Trial Design

Global tuberculosis drug development pipeline: the need and the reality

Publication: Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010 Jun 12;375(9731):2100-9. doi: 10.1016/S0140-6736(10)60359-9.

5/2010

Tags: Advocacy, Bedaquiline (TMC-207), Biomarkers, Childhood TB, Clinical Development, Editorials, Global Pipeline, MDR-TB, Moxifloxacin, Policy, Pretomanid/PA-824, Rifapentine, Sutezolid, Trial Design

Tuberculosis drug development: Progress, challenges, and the road ahead

Publication: Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinb). 2010 May;90(3):162-7. doi: 10.1016/j.tube.2010.03.003.

4/2010

Tags: Advocacy, Clinical Development, Editorials, Global Pipeline, MDR-TB, Policy

Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships

Publication: Brooks AD, Wells WA, McLean TD, et. al. Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships. 2010. Innovation Strategy Today 2010 Jan. 3:1-5.

1/2010

Tags: Advocacy, Policy, Regimen Change, TB Market

Toward an Optimized Therapy for Tuberculosis? Drugs in Clinical Trials and in Preclinical Development

Publication: Ma Z, Lienhardt C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med. 2009 Dec;30(4):755-68, ix. doi: 10.1016/j.ccm.2009.08.011.

12/2009

Tags: Advocacy, Clinical Development, Drug Discovery, Editorials, Global Pipeline, MDR-TB, TB-HIV

Assessment of global capacity to conduct tuberculosis drug development trials- do we have what it takes

Publication: van Niekerk C, Ginsberg A. Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes? Int J Tuberc Lung Dis. 2009 Nov;13(11):1367-72. http://www.ingentaconnect.com/content/iuatld/ijtld/2009/00000013/00000011/a

11/2009

Tags: Advocacy, Clinical Development, Policy

Assessment of the Effects of the Nitroimidazo-Oxazine PA-824 on

Publication: Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother. 2009 Sep;53(9):3726-33. doi: 10.1128/AAC.00112-09

6/2009

Tags: Advocacy, Clinical Development, Clinical Trial Results, Pretomanid/PA-824

Pages